Relative Bioavailability of Olodaterol and Fluconazole

Boehringer Ingelheim

Status and phase: Completed; Phase 1

Conditions: Healthy; Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Fluconazole; Drug: BI 1744

Study type: Interventional

Funder types: Industry

Identifiers

NCT01153724

2010-018528-18 (EudraCT Number)

1222.48

Details and patient eligibility

About

This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol

Enrollment: 35 patients

Sex: All

Ages: 21 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:

Healthy male and female volunteers

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

35 participants in 2 patient groups

Olodaterol

Experimental group

Treatment:

Drug: BI 1744

Olodaterol + Fluconazole

Experimental group

Treatment:

Drug: Fluconazole

Drug: BI 1744